Oxford-AstraZeneca vaccine (file photo)
Denmark decided not to resume using the Oxford-AstraZeneca vaccine.
Brostrom stated that ‘there is a possible cross-reaction between vaccines and low platelet counts. We also know that there is a temporary relationship. This happens one week to ten days after vaccination with AstraZeneca. ‘ Brostrom stated that ‘the decision is relevant. Most of the population in Denmark has been vaccinated and is under epidemic control. ‘
He said that ‘I can understand well that other countries are using vaccines’. The Danish Health Authority also said that ‘if the situation changes, then the vaccine can be reintroduced later’.
The European Union will negotiate with Pfizer to extend agreement for Kovid vaccinesEarlier, the head of the European Union Commission, Ursula von der Leyen, on Wednesday announced plans to extend an agreement with the Pfizer company for Kovid-19 vaccines. The term of this agreement is to be extended till 2023. Von der Leyen said that the European Union (EU) would start negotiations to buy 1.8 billion doses of Pfizer-BioNotech by 2023. The Pfizer-BioNotech company has been the mainstay of Europe’s vaccination campaign.
Von der Leyen expressed complete confidence in the technique used for the Pfizer-BioNotech vaccine. This technique is different from the technique used in the Oxford-AstraZeneca vaccine. He said that we need to focus on those techniques which have proved their impact.
Pfizer-BioNotech plans to provide an additional five million doses to the European Union in the second quarter of this year. These doses will be different from the 200 million doses already approved for the EU. The announcement is set to be welcomed by 27 EU member states amid fears of possible blood clots from the Oxford-AstraZeneca vaccine and delays in vaccine supplies.